Bionomics Phase II Clinical Trial to Provide Hope and Opportunity for Mesothelioma Sufferers
Monday, March 29, 2010
Bionomics, an Australian drug company focused on new treatments for cancer and serious disorders of the central nervous system, has announced they will initiate a phase II trial of BNC105 as second line chemotherapy for advanced malignant pleural mesothelioma (MPM). Bionomics has already commenced Phase II testing of the anti-cancer properties of BNC105 in renal cancer in the United States.
Mesothelioma is a rare, aggressive cancer primarily caused by exposure to airborne asbestos fibers. Symptoms of mesothelioma may not appear until up to 50 years after initial exposure to asbestos. Mesothelioma is highly aggressive and is resistant to many cancer treatments.
Dr. Anna Nowak, Professor at the Faculty of Medicine, University of Western Australia and the trial's Principal Investigator, said that an early clinical trial of BNC105 showed some promise in mesothelioma. She adds that "this Phase II trial will provide hope and an opportunity to participate in a research study for people with mesothelioma who do not have other options for treatment."
The study plans to test 60 patients at 12 centers in Australia. The trial is being conducted by Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre.
The primary objective is to determine the tumor response rate. Secondary endpoints include progression free survival, quality of life, overall survival and treatment duration. Bionomics anticipates reporting interim results of this study in mesothelioma patients early in 2011.
BNC105 Clinical Trial - Phase II
© MesotheliomaHelp.Net. All Rights Reserved. Reprinting or republication of this article or any portion of its content is permitted but must include the http://mesotheliomahelp.net/ link.
posted by Nancy Meredith
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment